Cereblon as the cellular target responsible for the anti-multiple myeloma activity of immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide)

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F14%3A00011083" target="_blank" >RIV/00023736:_____/14:00011083 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Cereblon as the cellular target responsible for the anti-multiple myeloma activity of immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide)
Original language description
The binding of immunomodulatory drugs (IMiDs) to CRBN is associated with cytotoxicity of IMiDs and is used to treat multiple myeloma (MM), myelodysplastic syndromes (MDS) and lymphomas. The CRBN gene consists of 1329 base pairs, 11 exons, and encodes a protein of 443 amino acids. Exons 10-11 code for binding site of IMiDs and exons 5-7 for binding site of DDB1. CRBN plays a key role in mediating the antiproliferative and immunomodulatory activities of IMiDs in MM cells and T cells, respectively. Two target proteins, the zinc finger-containing transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) have been recently revealed by analysis of MM cell lines treated with lenalidomide.
Czech name
—
Czech description
—

Project
<a href="/en/project/NT13836" target="_blank" >NT13836: The study of the myelodysplastic syndrome pathogenesis in patients with isolated del(5q) abnormality and the analysis of the effect of lenalidomide</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)